JP2024535467A5 - - Google Patents

Info

Publication number
JP2024535467A5
JP2024535467A5 JP2024519581A JP2024519581A JP2024535467A5 JP 2024535467 A5 JP2024535467 A5 JP 2024535467A5 JP 2024519581 A JP2024519581 A JP 2024519581A JP 2024519581 A JP2024519581 A JP 2024519581A JP 2024535467 A5 JP2024535467 A5 JP 2024535467A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
level
psoriatic arthritis
proteins
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535467A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045187 external-priority patent/WO2023055901A2/en
Publication of JP2024535467A publication Critical patent/JP2024535467A/ja
Publication of JP2024535467A5 publication Critical patent/JP2024535467A5/ja
Pending legal-status Critical Current

Links

JP2024519581A 2021-09-30 2022-09-29 Tyk2阻害剤に対する応答性を決定する方法 Pending JP2024535467A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163250735P 2021-09-30 2021-09-30
US63/250,735 2021-09-30
US202163257407P 2021-10-19 2021-10-19
US63/257,407 2021-10-19
US202263330308P 2022-04-12 2022-04-12
US63/330,308 2022-04-12
PCT/US2022/045187 WO2023055901A2 (en) 2021-09-30 2022-09-29 Methods for determining responsiveness to tyk2 inhibitors

Publications (2)

Publication Number Publication Date
JP2024535467A JP2024535467A (ja) 2024-09-30
JP2024535467A5 true JP2024535467A5 (cg-RX-API-DMAC7.html) 2025-10-01

Family

ID=84359787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519581A Pending JP2024535467A (ja) 2021-09-30 2022-09-29 Tyk2阻害剤に対する応答性を決定する方法

Country Status (5)

Country Link
US (1) US20240390369A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408527A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024535467A (cg-RX-API-DMAC7.html)
KR (1) KR20240070634A (cg-RX-API-DMAC7.html)
WO (1) WO2023055901A2 (cg-RX-API-DMAC7.html)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
RU2013114352A (ru) 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
EP2818473A4 (en) 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
US9296725B2 (en) 2012-05-24 2016-03-29 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
US20160159773A1 (en) 2013-07-30 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
BR112016004723B1 (pt) 2013-09-03 2022-08-30 Sareum Limited Compostos de pirrolidina ou morfolina e composição contendo os mesmos
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses

Similar Documents

Publication Publication Date Title
So et al. A pilot study of IL-1 inhibition by anakinra in acute gout
Sánchez-Aguilar et al. Effect of rosuvastatin on cytokines after traumatic head injury
Takeuchi et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
JP2013541010A (ja) グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
Ghantous et al. The efficiency of extended postoperative antibiotic prophylaxis in orthognathic surgery: a prospective, randomized, double-blind, placebo-controlled clinical trial
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
KR20170045750A (ko) 폐 사르코이드증 치료 방법
JP2023527542A5 (cg-RX-API-DMAC7.html)
Somisetty et al. Comparing the efficacy of intra-articular platelet-rich plasma and corticosteroid injections in the management of frozen shoulder: A randomized controlled trial
Jhun et al. Vitamin D attenuates pain and cartilage destruction in OA animals via enhancing autophagic flux and attenuating inflammatory cell death
Baggio et al. Correction of erythrocyte abnormalities in idiopathic calcium-oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans
Son et al. SAMiRNA targeting amphiregulin alleviate total-body-irradiation-induced renal fibrosis
Li et al. Cannabidiol-loaded hydrogel microneedle patches inhibit TRIM14/TRAF3/NF-κB axis for the treatment of psoriasis
Yang et al. Inhibition of hepatitis B virus through PPAR-JAK/STAT pathway modulation by electroacupuncture and tenofovir disoproxil fumarate combination therapy
US6258798B1 (en) Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
Bulanov et al. Successful Treatment With High-Dose Colchicine of a 101-Year-Old Patient Diagnosed With COVID-19 After an Emergency Cholecystectomy
IL314179A (en) Compositions and methods for the treatment of depression
Michot et al. A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (nicoumalone)
Shan et al. Fenofibrate maintains the integrity of the blood–brain barrier during cerebral ischemia–reperfusion injury by inhibiting Egr-1: SHAN ET AL.
JP3916563B2 (ja) P物質の投与を含む治療方法
JP6912875B2 (ja) ErbB4+炎症性マクロファージによって媒介される疾患の治療方法
CN115175678B (zh) 使用btk抑制剂及其组合治疗dlbcl的方法
Kim et al. Improvement effect of soyeom pharmacopuncture on gout via NLRP3 inflammasome regulation
RU2742116C1 (ru) Противокоронавирусное средство для комбинированной терапии COVID-19 (SARS-CoV-2).
US10213444B2 (en) Composition and method for treating bipolar disorder